James A. LebovitzDechert LLP : Lawyers
...James A. Lebovitz
...James A. LebovitzPartner
...James A. Lebovitz is a partner in the corporate and securities and mergers and acquisitions groups.He
focuses primarily on the representation of private and public life sciences, healthcare, technology, and growth companies and has extensive experience representing venture capital investors and investment banking firms.Mr. Lebovitz
has been recognized as a leading lawyer for corporate/M&A and private equity by Chambers USA, a referral guide to leading lawyers in the United States.In its 2008 edition, Chambers noted that "he
knows just how to get the deal done."Mr. Lebovitz is also recognized as a leading lawyer for corporate law, securities law, mergers and acquisitions law, leveraged buyouts and private equity law, and biotechnology law in The Best Lawyers in America and is listed for his extensive corporate finance experience in the 2007 and 2008 editions of The Legal 500 (U.S.), which notes that he is a "strong and experienced counselor."
, Mr. Lebovitz
is recognized for his
ability to capture and structure the capital life sciences companies need, including private placements and public offerings, to support the long development and commercialization process.He
also negotiates and executes strategic mergers, acquisitions, divestitures, spin-offs, joint ventures, and other strategic collaborations to enhance the development and commercialization of new technologies and scientific breakthroughs.In addition, Mr. Lebovitz has experience advising companies in the technology, real estate, and business and financial services industries. ,
, Mr. Lebovitz is the Chair of Dechert's firmwide lawyer hiring committee and previously served as partner responsible for associate development.From 2000 to 2005, he served as chair of the firm's business and technology practice group. ,
, Mr. Lebovitz joined Dechert in July 1999 as a partner in the Philadelphia office following three years as the general counsel of a national, publicly traded, physician practice management company. ,
, Professional Activities,Mr. Lebovitz is a former Trustee of the Philadelphia Museum of Art and of The Baldwin School and is a past President and current member of the Board of Trustees of the Samuel S. Fleisher Art Memorial.
Significant Representations In the last few years alone, Mr. Lebovitz
has advised on a wide range of domestic and international corporate finance and M&A transactions, including: ,, -- JP Morgan in its role as: underwriter in the $86 million initial public offering of Emergent BioSolutions Inc.; initial purchaser in the $125 million offering of convertible notes and common stock by Oscient Pharmaceuticals Corporation; and placement agent in the $88 million public offering by Genome Therapeutics, $40 million offering by Altair Nanotechnologies, $31.9 million registered direct offering by Barrier Therapeutics, Inc., $30 million public offering by ArQule, Inc., $33.8 and $23.9 million public offerings by Neose Technologies, and $27.6 million offering by Bioenvision, Inc.,
, -- Covance Inc.
, a leading clinical research organization (CRO) providing drug development services, in a $1.6 billion ten-year strategic alliance with Eli Lilly and Company
...Mr. Lebovitz is a graduate of Yale College (B.A.,1979), where he served as editor-in-chief of the Yale Daily News, the University of Virginia School of Law (J.D., 1982), where he served as notes editor of The Virginia Journal of International Law, and the University of Cambridge (LL.M., 1983).